🔬Deep Research
BIAF — BioAffinity Technologies Inc · catalysts, narrative & risks
Context
bioAffinity Technologies, Inc. (NASDAQ: BIAF, with BIAFW for warrants) is a micro-cap biotech based in San Antonio developing the non-invasive CyPath® Lung diagnostic test for early-stage lung cancer, marketed as a Laboratory Developed Test through its subsidiary Precision Pathology Laboratory Services [2][19]. As a small company, its share price and trading have been volatile, and at various points it traded below the level requiring intervention (see below). The following reflects sources dated roughly July–October 2026.
Recent catalysts (last ~1–3 months)
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →